SIGLANA Trademark

Trademark Overview

On Friday, April 23, 2010, a trademark application was filed for SIGLANA with the United States Patent and Trademark Office. The USPTO has given the SIGLANA trademark a serial number of 85021698. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, July 31, 2020. This trademark is owned by Glaxo Group Limited. The SIGLANA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines
siglana

General Information

Serial Number85021698
Word MarkSIGLANA
Filing DateFriday, April 23, 2010
Status710 - CANCELLED - SECTION 8
Status DateFriday, July 31, 2020
Registration Number4453077
Registration DateTuesday, December 24, 2013
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 19, 2010

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines
Translation of Words in MarkThe wording "SIGLANA" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, July 31, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events

Event DateEvent Description
Friday, July 31, 2020CANCELLED SEC. 8 (6-YR)
Monday, December 24, 2018COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 24, 2013REGISTERED-PRINCIPAL REGISTER
Tuesday, November 19, 20131(B) BASIS DELETED; PROCEED TO REGISTRATION
Monday, November 18, 2013NOTICE OF ALLOWANCE CANCELLED
Monday, November 18, 2013TEAS DELETE 1(B) BASIS RECEIVED
Saturday, June 8, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 7, 2013EXTENSION 5 GRANTED
Friday, May 31, 2013EXTENSION 5 FILED
Friday, May 31, 2013TEAS EXTENSION RECEIVED
Monday, March 25, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 25, 2013TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, March 25, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 25, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 9, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 8, 2013EXTENSION 4 GRANTED
Monday, December 3, 2012EXTENSION 4 FILED
Monday, December 3, 2012TEAS EXTENSION RECEIVED
Saturday, June 16, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 15, 2012EXTENSION 3 GRANTED
Monday, June 11, 2012EXTENSION 3 FILED
Monday, June 11, 2012TEAS EXTENSION RECEIVED
Tuesday, December 6, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 5, 2011EXTENSION 2 GRANTED
Wednesday, November 23, 2011EXTENSION 2 FILED
Wednesday, November 23, 2011TEAS EXTENSION RECEIVED
Wednesday, June 15, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 14, 2011EXTENSION 1 GRANTED
Wednesday, June 8, 2011EXTENSION 1 FILED
Tuesday, June 14, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 8, 2011TEAS EXTENSION RECEIVED
Tuesday, December 14, 2010NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 19, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 19, 2010PUBLISHED FOR OPPOSITION
Saturday, September 11, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, September 10, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 10, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 10, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 3, 2010ASSIGNED TO LIE
Tuesday, August 17, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 3, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 3, 2010NON-FINAL ACTION E-MAILED
Tuesday, August 3, 2010NON-FINAL ACTION WRITTEN
Tuesday, August 3, 2010ASSIGNED TO EXAMINER
Thursday, May 13, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 28, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 27, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

siglana pharmaceutical treatment substances disorders preparations diseases hormonal neurological gastrointestinal ophthalmic